Liraglutide alleviates diabetic cardiomyopathy in streptozotocin-induced diabetic rats by enhancing mitophagy mediated by the AMPK-Parkin signaling pathway

Figure 3 Liraglutide ameliorate cardiomyocyte apoptosis induced by high glucose + palmitic acid. A: Representative CCK8 images for optimum treatment dose of liraglutide (Lira: 200 nmol/L); B and C: Representative and quantitative analysis images of cell terminal deoxynucleotidyl transferase mediated dUTP nick end labeling staining for the three groups (scale bar: 50 μm); D, F and G: Representative Western blotting images of pro-caspase 3 and cleaved caspase 3, cytosolic-cytochrome C and mitosolic-cytochrome C in the three groups [control group (Con), high glucose (HG) + palmitic acid (PA; 25 mmol/L D-glucose plus 250 μmol/L palmitate), Lira (HG + PA with 200 nmol/L liraglutide)]; E, H and I: Quantification of the expression of the proteins including cleaved caspase 3, cytosolic-cytochrome C and mitosolic-cytochrome C. Values are presented as the mean ± SD. ^aP < 0.05; ^bP < 0.01; ^cP < 0.001. Con: Control group; HG: High glucose; PA: Palmitic acid.